Pharsight

1. Drug name - DOVATO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (5 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (7 years from now)
CN101346376A	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Jul, 2011 (11 years ago)
CN101212903A	VIIV HLTHCARE	Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
CN101212903B	VIIV HLTHCARE	Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
CN102245182A	VIIV HLTHCARE	Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate	Dec, 2029 (7 years from now)
CN102245182B	VIIV HLTHCARE	Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis	Dec, 2029 (7 years from now)
IN373756B	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
IN201838011858A	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
EP1852434A1	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP1852434B1	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP1852434A4	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP2527007B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3372281A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3187225B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3045206A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3284520A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3284520B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3187225A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3372281B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3045206B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2527007A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117B8	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117A4	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2465580A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2465580B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1950212B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)
EP1950212A4	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)
EP1950212A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)
EP2376080A1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080B1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080A4	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (8 years from now)

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE;300MG	TABLET;ORAL	Prescription

Pharsight

Drugs that contain Dolutegravir Sodium; Lamivudine

1. Drug name - DOVATO

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drugs that contain Dolutegravir Sodium; Lamivudine

1. Drug name - DOVATO

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.